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Intracellular Ca2+ signals critically control a plethora of cel-
lular functions, of which many impact cellular death and/or 
survival, processes often dysregulated in cancer [1]. In 
healthy cells, Ca2+ signaling is employed for normal cell 
physiology and survival functions [2]. Yet, when a cell is 
exposed to toxic stimuli or suffering from enduring cell 
stress, like irreparable DNA damage, the Ca2+-signaling 
toolbox can be rapidly switched from a “pro-survival” mo-
dus into a “pro-death” modus, thereby initiating demise 
pathways [3]. The highly dynamic nature of Ca2+ signaling 
allows cells to swiftly response to stress and damage, pre-
venting the survival of damaged cells and malignant trans-
formation that eventually results in tumor formation. Al-
terations in the expression, activity and regulation of Ca2+-
transport systems both at the plasma membrane and at 
organelles like the endoplasmic reticulum (ER) and mito-
chondria have been implicated in oncogenesis and neo-
plasia [1, 4]. These changes result in aberrant Ca2+-signaling 
events that could favor resistance to cell death, migration 
or senescence escape [5]. 
Over the last decade, we learnt that tight contacts and 
functional connections involving Ca2+ exchanges between 
the ER, the main intracellular Ca2+-storage organelle, and 
the mitochondria are pivotal for cell-fate decisions [3, 6-8]. 
These contact sites contain chaperone-coupled Ca2+-flux 
systems: the IP3 receptors (IP3Rs) at the ER side and the 
voltage-dependent anion channels (VDACs) at the mito-
chondrial outer membrane side [9]. These are con-
trolled/exploited by several cellular factors and regulatory 
proteins, including oncogenes and tumor suppressors [10-
12]. Basal Ca2+ fluxes between ER and mitochondria sustain 
anabolic pathways for mitochondrial metabolism, ensuring 
proper cell cycle progression [13]. Yet, continued elevated 
ER-mitochondrial Ca2+ transfers result in loss of mitochon-
drial membrane integrity and release of apoptogenic fac-
tors [14]. Tuned ER-mitochondrial Ca2+ transfer is therefore 
key to cells’ response to pro-apoptotic stimuli: the failure 
of which results in cell death resistance, as often observed 
in cancer cells [15, 16]. In fact, the efficacy of chemothera-
peutic agents and photodynamic therapy depends on the 
ability of these agents to elicit ER-mitochondrial Ca2+ ex-
changes [15]. In the context of apoptosis, previous work 
proposed unique roles for the type 3 IP3R isoform (IP3R3) 
[17] and type 1 VDAC isoform (VDAC1) [18] even though 
other IP3R isoforms can contribute to the initiation of cell 
death programs [19, 20]. 
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In some cells, the role played by the IP3R3 in pro-
apoptotic Ca2+ transfers from ER to mitochondria might 
relate to its ability to preferentially partner with the VDAC1 
complex [18]. Notably, several tumor suppressors and on-
cogenes located at the ER membranes dodge ER Ca2+ ho-
meostasis and dynamics [10, 21]. In general, tumor sup-
pressors increase ER-mitochondrial Ca2+ fluxes, whereas 
oncogenes suppress ER-mitochondrial Ca2+ fluxes. The ac-
tions of both tumor suppressors and oncogenes at the ER 
can involve changes of the steady-state ER Ca2+-filling state 
through modulation of sarco/endoplasmic reticulum Ca2+ 
ATPases (SERCA) and/or ER Ca2+-leak channels. For instance, 
during stress, the tumor suppressor p53 accumulates at 
the ER and enhances the Ca2+-pump activity SERCA, causing 
ER Ca2+ overload and the likelihood for pro-apoptotic ER-
mitochondrial Ca2+ fluxes [22-24]. The anti-apoptotic pro-
tein Bcl-2 increases IP3R phosphorylation and its sensitivity 
to IP3, enhancing the passive Ca
2+ leak from the ER, lower-
ing ER Ca2+ levels and so pro-apoptotic ER-mitochondrial 
Ca2+ fluxes [25]. Several tumor suppressors and oncogenes 
have been identified as direct regulators of the IP3R, 
whereby tumor suppressors (like BRCA1, PTEN, PML) and 
oncogenes (like Bcl-2, PKB/Akt) that respectively promote 
and suppress the activity of IP3R channels by impacting 
their gating and consequently their open probability [10, 
21]. Besides this direct regulation of IP3R gating, it is clear 
that total IP3R-protein levels impact Ca
2+ flux from the ER to 
the mitochondria and in turn cellular sensitivity to death as 
well. Insights are now available on IP3R degradation by ER-
assisted and 26S proteasomal turnover after cell stimula-
tion and IP3R activation [26]. In such conditions, IP3Rs be-
come ubiquitinated due to recruitment of the erlin1/2 
complex and RNF170, an E3 ubiquitin ligase [27-29].  
Hitherto, not much was known about the molecular 
mechanisms impacting basal IP3R turn-over and controlling 
their steady-state in stressed cells; equally, whether 
dysregulation of these mechanisms was involved in onco-
genesis and/or tumor progression. Nevertheless, it is clear 
that IP3R levels do impact apoptotic sensitivity [20, 30-32], 
and hence cell death and survival proteins were found im-
plicated in regulating IP3R levels [33, 34].  
Recent work from Kuchay et al. revealed an unexpected 
role for the tumor suppressor lipid/protein phosphatase 
PTEN, an allele frequently lost in cancer [35] and well-
known negative regulator of PKB/Akt signaling, stabilizing 
IP3R channels by protecting them from proteasomal degra-
dation [36] (Fig. 1). This novel function adds to its recently 
discovered presence at the mitochondria-associated mem-
branes (MAMs), where it contributes to cell death sensitivi-
ty by suppressing IP3R3-mediated Ca
2+ fluxes [37]. Inde-
pendently of its catalytic activity, PTEN competes with the 
F-box protein FBXL2 (the receptor subunit of one of 69 
human SCF (SKP1, CUL1, F-box protein) [38, 39] to bind to 
IP3R3 channels, in particular to a region in the ligand-
binding domain. Normal cells that express PTEN will have a 
low level of the IP3R3/FBXL2-complex formation, prevent-
ing the ubiquitination of IP3R3 channels and subsequent 
targeting to the proteasome. Consistently with previous 
observations [27, 40], activation of cells with agonists in-
crease FBXL2/IP3R3-complex formation and subsequent 
IP3R3 post-transcriptional regulation via ubiquitination 
similarly to RNF170-mediated ubiquitination of IP3Rs [27]. 
Interestingly, FBXL2 activity itself is Ca2+ dependent, but 
antagonized by calmodulin [41]. Hence, activation of IP3Rs 
may not only make these channels more susceptible for 
degradation by increased interaction with FBXL2 but re-
lease of Ca2+ itself through IP3Rs may trigger local activa-
tion of FBXL2 associated with IP3R3 leading to IP3R3 degra-
dation. Notably, FBXL2 binding to its substrates (like cyclin 
D3) was found to occur via canonical calmodulin-binding 
motif thereby preventing ubiquitination. It is nonetheless 
likely that FBXL2 binding to IP3Rs does not occur by target-
ing its calmodulin-binding motif even though a role for 
calmodulin in regulating IP3R3/FBXL2-complex formation 
may not be ruled out. In any case, access to the degron 
region in the ligand-binding core of IP3R3 for FBXL2 is facili-
tated by deletion of the suppressor domain and loss of 
PTEN is associated with increased FBXL2 binding to IP3R3 
and degradation of IP3R3, contributing to the apoptotic 
resistance of cells [36]. In cancer cells lacking PTEN, FBXL2 
knockdown could therefore restore IP3R3 levels and apop-
totic sensitivity.  
Notably, authors show that by mutating the degron re-
gion in the ligand-binding domain in IP3R3 the FBXL2 bind-
ing and IP3R3 degradation were both prevented. Using a 
knockin approach in which wild-type IP3R3 was altered into 
a non-degradable IP3R3 mutant version 
(IP3R3
Q550A/F553A/R554A), the authors could restore the rise of 
Ca2+ induced by photodynamic therapy and apoptosis in 
PTEN-negative cancer cells. This correlation was eloquently 
observed in human tumor samples beyond the convincing 
in vivo xenograft models, in which tumor cells expressing a 
non-degradable IP3R3 version or treated with geranyl-
geranyltransferase inhibitor (that prevents FBXL2 accumu-
lation at ER membranes and activity, which depends on its 
geranylgeranylation [42]) were greatly sensitized towards 
photodynamic therapy compared to tumor cells expressing 
wild-type (degradable) IP3R3 or untreated tumors.  
It is important to note that FBXL2 has been previously 
implicated in cancer, but rather acting via the suppression 
of cell cycle progression and proliferation, as observed in 
lung tumors [43], leukemic cells [44], gastric cancer cells 
[45], and prevalently of tumor suppressive nature. Instead, 
in this work, the effects of FBXL2 on IP3R3 are tumor pro-
moting by increasing IP3R3 degradation and making the 
cells more resistant to cell death [36]. These effects are 
neutralized by PTEN, which prevents FBLX2 binding to 
IP3R3 channels. This interference by PTEN is likely selective 
for IP3R3 and not for other FBXL2 targets regulating the cell 
cycle. Nevertheless, the anti-cancer properties of FBXL2 
activators like the small molecule BC-1258 [46] will be ad-
versely impacted by FBXL2-mediated IP3R3 degradation, 
likely limiting their application to PTEN-positive cancers. 
Vice versa, the previously discovered tumor suppressive 
properties of FBXL2 in cancer might be further boosted if 
FBXL2  could be  selectively/subcellularly  activated to  pro- 
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FIGURE 1: IP3R3 channels are targets for ubiquitination and deubiquitylation enzymes, whose activities are deregulated in cancer cells, thereby 
impacting IP3R3 stability and ultimately cell death sensitivity. (A) IP3Rs, located at the ER-mitochondrial interface, here particularly IP3R3, promote 
ER-mitochondrial Ca2+ fluxes, thereby enabling adequate cell death sensitivity in healthy cells undergoing genotoxic stress and cell damage, an im-
portant feature that prevents oncogenesis. The levels of IP3R3 channels are critical for this process and are dynamically regulated via ubiquitination. 
BAP1, a tumor suppressor with deubiquitylation enzyme activities and frequently mutated in cancers including mesothelioma, deubiquitylates IP3R3, 
preventing its proteasomal degradation and resulting in IP3R3 stabilization. In contrast, FBXL2, an F-Box protein with ubiquitin ligase activity, ubiqui-
tinates IP3R3, directing it for proteasomal degradation and resulting in a decline in IP3R3 levels. Importantly, PTEN, another tumor suppressor that 
antagonizes Akt signaling and frequently mutated in a variety of cancers including prostate cancer, competes with FBXL2 for IP3R3 binding and thus 
antagonizes FBXL2-mediated ubiquitination of IP3R3, stabilizing IP3R3. In healthy cells, it is anticipated that the balance between deubiquitylation and 
ubiquitination of IP3R3 channels is favored towards deubiquitylated IP3R3, enabling sufficient IP3R3 channels to sustain adequate ER-mitochondrial 
Ca2+ fluxes in cells undergoing genotoxic stress and cell damage to engage cell death and eradicate pre-malignant cells with DNA damage. (B) Several 
cancer types display chromosomal aberrations with defects in the expression of several tumor suppressors, including a reduction in BAP1 levels and 
a loss in PTEN expression. As a consequence, both alterations will favor IP3R3 ubiquitination and degradation, since reduced BAP1 levels will lead to 
reduced deubiquitylation of IP3Rs and loss of PTEN will enable FBXL2 to mediate IP3R3 ubiquitination. As a consequence, the balance between ubiq-
uitination and deubiquitylation of IP3R3s will shift towards ubiquitinated IP3R3, impairing ER-mitochondrial Ca
2+ fluxes that are needed to engage cell 
death programs in response to genotoxic stress and cell damage. As such, cells will be able to withstand this cellular stress, resulting in their survival 
and proliferation despite accumulated DNA damage. This phenomenon is an early event in oncogenesis, enabling malignant cell formation and tu-
moral behavior. 
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mote its cell-cycle targets while shielding IP3R3 for degra-
dation.   
In a separate study, Bononi et al. revealed a novel 
deubiquitylating enzyme that actually counteracts the level 
of IP3R3 ubiquitination, namely BRCA-associated protein 1 
(BAP1) [47] (Fig. 1). BAP1 is a potent tumor suppressor, 
which protects against environmental stress and damage 
[48]. Loss of one BAP1 allele either inherited or acquired 
during life has been associated with environmental stress-
induced carcinogenesis, like UV light for uveal melanoma 
and asbestos for mesothelioma. Germline mutations in 
BAP1 resulting in aberrant/loss of BAP1 expression were 
associated with a high incidence of familial mesothelioma 
and uveal melanoma, while somatic mutations in BAP1 
were found in sporadic mesotheliomas [49]. Germline mu-
tations in BAP1 greatly enhanced the sensitivity of mice to 
develop mesothelioma when exposed to asbestos [50]. 
Recently, it has been shown in patient fibroblasts that loss 
of BAP1 displayed a metabolic rewiring towards aerobic 
glycolysis and reduced mitochondrial respiration associat-
ed with malignancy and carcinogenesis [51]. BAP1 was 
therefore identified as a novel IP3R3-interacting protein 
that impacts its post-translational modification. BAP1 
causes IP3R3 stabilization and prevents the channel to be 
degraded by the proteasome. Loss of only 1 allele in BAP1 
is sufficient to protect cells from undergoing apoptotic cell 
death via suppressed Ca2+ release triggered by apoptotic 
stimuli like H2O2. An effect operated via the IP3R3 degrada-
tion due to a decreased BAP1-mediated deubiquitylation of 
IP3R3. As a consequence, exposure of cells being BAP1
+/- to 
DNA-damaging conditions will result in a higher percentage 
of cells surviving despite having damaged DNA. Such cells 
bearing genomic aberrations are at high risk for neoplastic 
behavior and oncogenesis, resulting in malignant cell 
growth and tumor formation. However, restoring IP3R3 in 
these cells could be an attractive strategy to reinstate cell 
death sensitivity of BAP1+/- cells.  
Based on these recent developments, it will be there-
fore important to examine the interplay between BAP1 and 
FBXL2. It is indeed not clear whether the increased IP3R3 
ubiquitination observed when BAP1 levels are declined is 
mediated through FBXL2 and whether lack of BAP1 results 
in increased FBXL2 association with IP3R3 channels. In any 
case, by inhibiting FBXL2’s action on IP3R3 without inhibit-
ing its action on cell cycle targets could be an attractive 
avenue to restore IP3R3 levels in these cancers. Another 
strategy can be boosting ER Ca2+-store loading in tumor 
cells by activating the SERCA pumps, thereby increasing the 
likelihood for ER-mitochondrial Ca2+ fluxes and restoring 
cellular sensitivity to apoptosis [22, 52]. Tumor-selective 
SERCA modulation is challenging but not impossible though, 
as evidenced by the ability to locally release thapsigargin in 
the vicinity of pancreatic tumor cells using peptide-coupled 
prodrugs that are enzymatically cleaved by prostate-
specific factors [53]. SERCA-activating approaches may be 
based on p53, recently proposed to activate SERCA activity 
in response to chemotherapy [22-24], although p53 is very 
frequently mutated in cancer. In wild-type p53 tumors, 
direct p53 activators might be of use. Other solace may 
come from SERCA-activating small molecules like CDN1163 
[54], provided these agents can be delivered to tumor cells 
while sparing healthy cells [52].  
These recent papers highlight that deregulation of 
IP3R3 ubiquitination homeostasis not only impacts death 
and survival of cells but also contributes to the oncogenic 
behavior of cells with dysfunctional tumor suppressors by 
either (i) lacking PTEN [36] or by (ii) displaying deficiencies 
in BAP1 [47]. They underpin the emerging role of altered 
Ca2+ signaling at the MAM level as a key event in apoptosis 
resistance that contributes early events associated with 
oncogenesis and tumor formation. Challenging will be the 
translation of these insights into anti-cancer therapies for 
which not only tumor-selective applications will be re-
quired but also further understanding in the selective tar-
geting at the level of the IP3R3. 
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